For all studies involving more than one patient, it is advised to contact us for discussing about your project, and ensure a correct calculation of KELIM values in your studies.
For pharmaceutical companies developing innovative drugs in ovarian cancer (or other cancers), we would be happy to work with you for analyzing the modeled CA-125 kinetics (or other markers), and define the prognostic value regarding the efficacy of your treatment.
For all inquiries, please send us an e-mail at:
biomarkers.kinetics@univ-lyon1.frUniversité Claude Bernard Lyon-1
Faculté de Médecine et Maïeutique Charles Mérieux
Chemin du Petit Revoyet
69921 OULLINS (FRANCE)